Literature DB >> 28523338

[How long should we wait upon completion of chemoradiotherapy before assessment of tumor response in anal cancer?]

Daniel Martin1, Claus Rödel1, Emmanouil Fokas2.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28523338     DOI： 10.1007/s00066-017-1149-2

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  7 in total

1.  Human papilloma virus load and PD-1/PD-L1, CD8+ and FOXP3 in anal cancer patients treated with chemoradiotherapy: Rationale for immunotherapy.

Authors:  Panagiotis Balermpas; Daniel Martin; Ulrike Wieland; Margret Rave-Fränk; Klaus Strebhardt; Claus Rödel; Emmanouil Fokas; Franz Rödel
Journal:  Oncoimmunology       Date:  2017-02-06       Impact factor: 8.110

2.  The 5Rs of radiobiology.

Authors:  G G Steel; T J McMillan; J H Peacock
Journal:  Int J Radiat Biol       Date:  1989-12       Impact factor: 2.694

3.  Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research.

Authors: 
Journal:  Lancet       Date:  1996-10-19       Impact factor: 79.321

4.  Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups.

Authors:  H Bartelink; F Roelofsen; F Eschwege; P Rougier; J F Bosset; D G Gonzalez; D Peiffert; M van Glabbeke; M Pierart
Journal:  J Clin Oncol       Date:  1997-05       Impact factor: 44.544

5.  Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study.

Authors:  M Flam; M John; T F Pajak; N Petrelli; R Myerson; S Doggett; J Quivey; M Rotman; H Kerman; L Coia; K Murray
Journal:  J Clin Oncol       Date:  1996-09       Impact factor: 44.544

6.  Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.

Authors:  Roger D James; Robert Glynne-Jones; Helen M Meadows; David Cunningham; Arthur Sun Myint; Mark P Saunders; Timothy Maughan; Alec McDonald; Sharadah Essapen; Martin Leslie; Stephen Falk; Charles Wilson; Simon Gollins; Rubina Begum; Jonathan Ledermann; Latha Kadalayil; David Sebag-Montefiore
Journal:  Lancet Oncol       Date:  2013-04-09       Impact factor: 41.316

7.  Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial.

Authors:  Robert Glynne-Jones; David Sebag-Montefiore; Helen M Meadows; David Cunningham; Rubina Begum; Fawzi Adab; Kim Benstead; Robert J Harte; Jill Stewart; Sandy Beare; Allan Hackshaw; Latha Kadalayil
Journal:  Lancet Oncol       Date:  2017-02-11       Impact factor: 41.316
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.